Selective MC4R Peptide Agonists for Obesity and Cognitive Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing MC4R agonists face challenges in selective binding due to similarities among melanocortin receptor subtypes, leading to varied biological responses and side effects, with few providing effective treatment for obesity and neurodegenerative diseases.
Innovation Solution
Development of novel peptides, such as Ac-Arg-cyclo[Asp-Pip-D-Phe-(4-Cl)-βArg-βTrp-Lys]-NH2, featuring beta-amino acids and site-specific modifications, enhancing selectivity and potency for MC4R activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MC4R agonists are used, then appetite control function is activated, but selectivity among melanocortin receptor subtypes is poor leading to side effects
Solution Approach 1:
The patent introduces site-specific modifications at particular positions of the MC4R agonist peptide sequence, such as substituting specific amino acids with beta-amino acids or introducing specific chemical groups at defined positions. This local modification approach enhances selectivity for MC4R while minimizing interactions with other melanocortin receptor subtypes, thereby reducing side effects associated with off-target binding.
Solution Approach 2:
The patent systematically varies chemical parameters of the agonist molecules, including amino acid composition, cyclic structure configuration, and side chain modifications. By optimizing these parameters, the patent achieves enhanced binding selectivity for MC4R compared to other melanocortin receptor subtypes (MC1R, MC2R, MC3R, MC5R),从而减少脱靶效应和副作用。
2Adaptability or versatility
If MC4R agonists are developed to treat obesity, then appetite control is improved, but effectiveness for neurodegenerative diseases is insufficient
Solution Approach 1:
The patent designs MC4R agonists with the capability to address multiple therapeutic indications. By optimizing the peptide structure to achieve high potency and selectivity for MC4R, the patent enables a single agent to potentially treat both metabolic disorders (obesity, type 2 diabetes) and neurodegenerative diseases, leveraging the receptor's role in both energy homeostasis and neuronal protection.
3Manufacturing precision
If peptide structure is modified to enhance selectivity, then binding specificity increases, but synthesis complexity increases
Solution Approach 1:
The patent employs cyclic peptide structures with defined ring sizes and specific amino acid sequences that can be synthesized using modular approaches. The cyclic structure provides structural rigidity that enhances binding specificity while the modular nature of peptide synthesis allows for systematic modification of specific residues without requiring complete de novo synthesis, thereby managing complexity.
Data Source
AI summary
Novel peptides having an extra Arg improve the melanocortin 4 receptor (MC4R) selectivity and potency are described herein. The peptides are used in compositions and methods for treating obesity and/or neurodegenerative diseases. A selective MC4R peptide agonist is administered to a subject in need of such treatment.